190 related articles for article (PubMed ID: 11014096)
1. [What's new in hormone replacement therapy for postmenopausal women? I. Advantages of hormone replacement therapy (HRT)].
Martin-Du Pan RC; Luzuy F
Rev Med Suisse Romande; 2000 Jun; 120(6):515-21. PubMed ID: 11014096
[TBL] [Abstract][Full Text] [Related]
2. [What's new in hormone replacement therapy of postmenopausal women? II. Risks of hormone replacement therapy (HRT)].
Martin-Du Pan RC; Luzuy F
Rev Med Suisse Romande; 2000 Jun; 120(6):523-7. PubMed ID: 11014097
[TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
4. [Influence of nomegestrol acetate on the improvement of the quality of life induced by estrogen therapy in menopausal women].
Reginster JY; Zartarian M; Colau JC
Contracept Fertil Sex; 1996 Nov; 24(11):847-51. PubMed ID: 8991589
[TBL] [Abstract][Full Text] [Related]
5. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
6. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
Reginster JY
J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
[TBL] [Abstract][Full Text] [Related]
7. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
Koledova VV; Khalil RA
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
[TBL] [Abstract][Full Text] [Related]
8. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
[TBL] [Abstract][Full Text] [Related]
9. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause.
Woo J; Lau E; Ho SC; Cheng F; Chan C; Chan AS; Haines CJ; Chan TY; Li M; Sham A
Menopause; 2003; 10(4):352-61. PubMed ID: 12851519
[TBL] [Abstract][Full Text] [Related]
11. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk.
Silvestri A; Gambacciani M; Vitale C; Monteleone P; Ciaponi M; Fini M; Genazzani AR; Mercuro G; Rosano GM
Maturitas; 2005 Apr; 50(4):305-11. PubMed ID: 15780531
[TBL] [Abstract][Full Text] [Related]
12. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
Kwok S; Charlton-Menys V; Pemberton P; McElduff P; Durrington PN
Maturitas; 2006 Mar; 53(4):439-46. PubMed ID: 16139447
[TBL] [Abstract][Full Text] [Related]
13. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms.
de Paula FJ; Soares JM; Haidar MA; de Lima GR; Baracat EC
Maturitas; 2007 Jan; 56(1):69-77. PubMed ID: 16822626
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
15. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
16. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
[TBL] [Abstract][Full Text] [Related]
17. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
18. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study.
Koh KK; Han SH; Shin MS; Ahn JY; Lee Y; Shin EK
Eur Heart J; 2005 Jul; 26(14):1362-8. PubMed ID: 15872028
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid composition of serum phospholipid of premenopausal women and postmenopausal women receiving and not receiving hormone replacement therapy.
Stark KD; Park EJ; Holub BJ
Menopause; 2003; 10(5):448-55. PubMed ID: 14501607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
